The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors
Open Access
- 2 July 2007
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 117 (7) , 1884-1892
- https://doi.org/10.1172/jci30068
Abstract
A subset of CC chemokines, acting through CC chemokine receptors (CCRs) 1 to 5, is instrumental in shaping inflammatory responses. Recently, we and others have demonstrated that the atypical chemokine receptor D6 actively sequesters and destroys many of these proinflammatory CC chemokines. This is critical for effective resolution of inflammation in vivo. Inflammation can be protumorigenic, and proinflammatory CC chemokines have been linked with various aspects of cancer biology, yet there is scant evidence supporting a critical role for these molecules in de novo tumor formation. Here, we show that D6-deficient mice have increased susceptibility to cutaneous tumor development in response to chemical carcinogenesis protocols and, remarkably, that D6 deletion is sufficient to make resistant mouse strains susceptible to invasive squamous cell carcinoma. Conversely, transgenic D6 expression in keratinocytes dampens cutaneous inflammation and can confer considerable protection from tumor formation in susceptible backgrounds. Tumor susceptibility consistently correlated with the level of recruitment of T cells and mast cells, cell types known to support the development of skin tumors in mice. These data demonstrate the importance of proinflammatory CC chemokines in de novo tumorigenesis and reveal chemokine sequestration by D6 to be a novel and effective method of tumor suppression.Keywords
This publication has 49 references indexed in Scilit:
- Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6Proceedings of the National Academy of Sciences, 2007
- The Chemokine Receptor D6 Has Opposing Effects on Allergic Inflammation and Airway ReactivityAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Essential contribution of a chemokine, CCL3, and its receptor, CCR1, to hepatocellular carcinoma progressionInternational Journal of Cancer, 2005
- CXC chemokines in angiogenesisCytokine & Growth Factor Reviews, 2005
- Human mast cell chemokines receptors: implications for mast cell tissue localization in asthmaClinical and Experimental Allergy, 2005
- NF-κB functions as a tumour promoter in inflammation-associated cancerNature, 2004
- Kaposi sarcoma herpesvirus–induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcomaNature Genetics, 2004
- The Distinct Contributions of Murine T Cell Receptor (TCR)γδ+ and TCRαβ+ T Cells to Different Stages of Chemically Induced Skin CancerThe Journal of Experimental Medicine, 2003
- CC Chemokine Receptor (CCR)4 and the CCR10 Ligand Cutaneous T Cell–attracting Chemokine (CTACK) in Lymphocyte Trafficking to Inflamed SkinThe Journal of Experimental Medicine, 2001
- The Biology of Chemokines and their ReceptorsAnnual Review of Immunology, 2000